Benicar Shortage: What Providers and Prescribers Need to Know in 2026

Benicar (Olmesartan) Supply Briefing for Providers

Availability of blood pressure medications shouldn't be a barrier to patient adherence — but in 2026, providers are fielding more questions about Benicar (Olmesartan Medoxomil) supply disruptions than ever. This briefing covers the current state of Olmesartan availability, prescribing implications, cost considerations, and tools to help your patients maintain access to their therapy.

Current Supply Status at a Glance

• Generic Olmesartan tablets (5 mg, 20 mg, 40 mg): Generally available from multiple generic manufacturers. Not currently on the FDA drug shortage list.
• Brand Benicar: Rarely stocked by pharmacies; the market has shifted almost entirely to generics since patent expiration in 2016.
• Combination products affected: Torrent Pharma discontinued multiple presentations of the Amlodipine/Hydrochlorothiazide/Olmesartan combination tablet (generic Tribenzor) in 2024–2025. Other combination products (Benicar HCT, Azor generics) may experience intermittent supply disruptions.

Shortage Timeline

2016: Patent Expiration

Benicar's patent expired, opening the market to generic manufacturers. This dramatically reduced the cost of Olmesartan and improved overall availability.

2024–2025: Combination Product Discontinuations

Torrent Pharma discontinued several presentations of the triple-combination tablet (Amlodipine/HCTZ/Olmesartan). This affected patients on fixed-dose combination therapy and created the need for prescription adjustments.

2026: Localized Supply Disruptions

While standalone Olmesartan remains broadly available, ongoing generic manufacturer consolidation and distributor allocation practices have created intermittent, localized shortages. Patients may encounter pharmacies that are temporarily out of stock, particularly for specific generic brands or combination formulations.

Prescribing Implications

Standalone vs. Combination Products

If your patient is currently on a combination product that has been discontinued, the most practical approach is to prescribe the components separately:

• Benicar HCT → Olmesartan + Hydrochlorothiazide (two separate generics)
• Azor → Olmesartan + Amlodipine (two separate generics)
• Tribenzor → Olmesartan + Amlodipine + Hydrochlorothiazide (three separate generics)

This increases pill burden but ensures each component remains accessible and independently sourceable.

Therapeutic Substitution Considerations

When Olmesartan is unavailable, the following ARB equivalencies can guide therapeutic substitution:

• Olmesartan 20 mg ≈ Losartan 50 mg ≈ Valsartan 80–160 mg ≈ Irbesartan 150 mg ≈ Telmisartan 40 mg
• Olmesartan 40 mg ≈ Losartan 100 mg ≈ Valsartan 160–320 mg ≈ Irbesartan 300 mg ≈ Telmisartan 80 mg

These are approximate equivalencies. Individual patient response may vary, and blood pressure should be monitored within 2–4 weeks of any switch.

Sprue-Like Enteropathy Reminder

The FDA issued a safety communication in 2013 regarding Olmesartan-associated sprue-like enteropathy, characterized by severe chronic diarrhea, weight loss, and villous atrophy on intestinal biopsy. This adverse effect is unique to Olmesartan and has not been associated with other ARBs. Symptoms can develop months to years after initiation. If a patient on Olmesartan presents with unexplained chronic diarrhea, consider this diagnosis and discontinue the medication.

The Availability Picture

The current landscape for Olmesartan varies by product type:

• High availability: Standalone generic Olmesartan 5 mg, 20 mg, 40 mg tablets
• Moderate availability: Generic Olmesartan/HCTZ (Benicar HCT equivalent), Generic Olmesartan/Amlodipine (Azor equivalent)
• Low availability: Triple combination Olmesartan/Amlodipine/HCTZ (Tribenzor equivalent), Brand-name Benicar

Providers can direct patients to Medfinder for Providers to check real-time pharmacy stock and help patients locate their medication.

Cost and Access Considerations

Understanding the cost landscape helps set patient expectations:

• Generic Olmesartan 20 mg (30 tablets): $10–$15 with discount coupon
• Generic Olmesartan 40 mg (30 tablets): $11–$17 with discount coupon
• Generic Olmesartan 90-day supply: $16–$22 via mail-order pharmacy
• Brand Benicar (30 tablets): $200–$350 (rarely dispensed)

Most commercial and Medicare plans cover generic Olmesartan as a Tier 1 or Tier 2 preferred generic. Some plans may prefer Losartan (Tier 1) and require step therapy before covering Olmesartan. If your patient's plan requires prior authorization, document prior intolerance to Losartan or a clinical rationale for Olmesartan-specific therapy.

Patient Assistance

For uninsured or underinsured patients:

• Coupon cards: GoodRx, SingleCare, and other discount programs can bring generic Olmesartan to $10–$15 per month
• Daiichi Sankyo Patient Assistance Program (AccessCentral): May cover brand Benicar for eligible patients
• NeedyMeds and RxAssist: Directories of additional assistance programs

Tools and Resources for Your Practice

• Medfinder for Providers — real-time pharmacy stock checking to help patients locate medications
• FDA Drug Shortage Database — official shortage listings and estimated resupply dates
• ASHP Drug Shortage Resource Center — clinical guidance on managing drug shortages

Consider sharing these patient-facing resources with your staff:

• How to Find Benicar in Stock Near You
• How to Save Money on Benicar in 2026
• Alternatives to Benicar If You Can't Fill Your Prescription

Looking Ahead

The generic Olmesartan market is expected to remain stable for standalone formulations. However, the trend of manufacturer consolidation and product discontinuations in the combination product space may continue. Providers should be prepared to:

• Prescribe individual components when combination products become unavailable
• Consider therapeutic alternatives within the ARB class based on individual patient needs
• Monitor patient adherence more closely during supply disruptions, as gaps in blood pressure medication increase cardiovascular risk

Final Thoughts

While Olmesartan supply is not in crisis, the evolving generic landscape requires proactive management. Familiarize your team with the tools available at Medfinder for Providers to help patients navigate availability challenges efficiently.

Additional provider resources:

• How to Help Your Patients Find Benicar in Stock: A Provider's Guide
• How to Help Patients Save Money on Benicar: A Provider's Guide